company background image
TRDA

Entrada Therapeutics NasdaqGM:TRDA Stock Report

Last Price

US$17.17

Market Cap

US$538.1m

7D

22.0%

1Y

-20.2%

Updated

07 Dec, 2022

Data

Company Financials +
TRDA fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

TRDA Stock Overview

Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases.

Entrada Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Entrada Therapeutics
Historical stock prices
Current Share PriceUS$17.17
52 Week HighUS$24.38
52 Week LowUS$5.12
Beta0
1 Month Change-22.13%
3 Month Change19.65%
1 Year Change-20.18%
3 Year Changen/a
5 Year Changen/a
Change since IPO-28.31%

Recent News & Updates

Recent updates

We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate

Sep 11
We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate

We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate

May 28
We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate

We Think Entrada Therapeutics (NASDAQ:TRDA) Can Afford To Drive Business Growth

Jan 31
We Think Entrada Therapeutics (NASDAQ:TRDA) Can Afford To Drive Business Growth

Shareholder Returns

TRDAUS BiotechsUS Market
7D22.0%1.9%-0.4%
1Y-20.2%-11.2%-20.6%

Return vs Industry: TRDA underperformed the US Biotechs industry which returned -6.5% over the past year.

Return vs Market: TRDA underperformed the US Market which returned -17.6% over the past year.

Price Volatility

Is TRDA's price volatile compared to industry and market?
TRDA volatility
TRDA Average Weekly Movement13.7%
Biotechs Industry Average Movement11.1%
Market Average Movement7.4%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market3.3%

Stable Share Price: TRDA is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.

Volatility Over Time: TRDA's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2016124Dipal Doshihttps://www.entradatx.com

Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company’s lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1.

Entrada Therapeutics, Inc. Fundamentals Summary

How do Entrada Therapeutics's earnings and revenue compare to its market cap?
TRDA fundamental statistics
Market CapUS$538.08m
Earnings (TTM)-US$88.43m
Revenue (TTM)n/a

0.0x

P/S Ratio

-6.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
TRDA income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$88.43m
Earnings-US$88.43m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.82
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did TRDA perform over the long term?

See historical performance and comparison